Drug Type Small molecule drug |
Synonyms HSK 21542, HSK-21542, HSK21542 + [1] |
Target |
Mechanism κ opioid receptor agonists(Kappa opioid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationPriority Review (CN) |
Molecular FormulaC39H57N7O5 |
InChIKeyVWXDZAZSCZVCPV-YFRBGRBWSA-N |
CAS Registry2269511-95-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Uremic pruritus | NDA/BLA | CN | 23 Sep 2024 | |
Chronic Kidney Disease-Associated Pruritus | NDA/BLA | CN | 26 Jun 2024 | |
Pain, Postoperative | NDA/BLA | CN | 18 Oct 2023 | |
Pain | Phase 3 | CN | 08 Jun 2022 | |
Pruritus | Phase 2 | CN | 28 Feb 2024 | |
Liver Diseases | Phase 2 | CN | 16 Sep 2021 | |
Analgesia | Phase 2 | CN | 01 Jul 2020 | |
Chronic Kidney Diseases | Phase 1 | CN | 10 Oct 2023 | |
Acute Pain | Phase 1 | CN | 23 Apr 2023 | |
Uremia | Phase 1 | CN | 15 Jun 2021 |
Phase 1 | 6 | [14C]HSK21542 2 μg/0.212 μCi/kg | bracvynuck(hbpzuqdqjx) = nldpzydymb hbqnztbtyw (enqppjvuax ) View more | - | 01 Nov 2023 | ||
Phase 2 | - | 41 | iqwycwcpcn(uvfmsttisw) = dxitdfmzlp vftntxhklb (jfdjeuwmpz ) | Positive | 01 Jan 2023 | ||
iqwycwcpcn(uvfmsttisw) = fgcfvqnnon vftntxhklb (jfdjeuwmpz ) |